gamma-aminobutyric acid has been researched along with Acute Relapsing Multiple Sclerosis in 11 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report 11 MS patients with trigeminal neuralgia (TN): 6 intolerant to a therapeutic dosage of CBZ, showing serious adverse effects and subsequently treated with a combination of low-dose CBZ and gabapentin (GBP) (group 1); 5 treated with lamotrigine (LMT), showing adverse effects and subsequently treated with GBP (group 2)." | 7.70 | Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. ( Leandri, M; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 2000) |
| " We report 11 MS patients with trigeminal neuralgia (TN): 6 intolerant to a therapeutic dosage of CBZ, showing serious adverse effects and subsequently treated with a combination of low-dose CBZ and gabapentin (GBP) (group 1); 5 treated with lamotrigine (LMT), showing adverse effects and subsequently treated with GBP (group 2)." | 5.31 | Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. ( Leandri, M; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 2000) |
| " We report 11 MS patients with trigeminal neuralgia (TN): 6 intolerant to a therapeutic dosage of CBZ, showing serious adverse effects and subsequently treated with a combination of low-dose CBZ and gabapentin (GBP) (group 1); 5 treated with lamotrigine (LMT), showing adverse effects and subsequently treated with GBP (group 2)." | 3.70 | Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. ( Leandri, M; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 2000) |
| "Nabilone or placebo was titrated over 4 weeks (0." | 2.80 | Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. ( Doupe, M; Esfahani, F; Ethans, K; Galloway, K; Gomori, A; Namaka, M; Torabi, M; Turcotte, D, 2015) |
| "Nabilone was well tolerated, with dizziness/drowsiness most frequently reported." | 2.80 | Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. ( Doupe, M; Esfahani, F; Ethans, K; Galloway, K; Gomori, A; Namaka, M; Torabi, M; Turcotte, D, 2015) |
| " We report 11 MS patients with trigeminal neuralgia (TN): 6 intolerant to a therapeutic dosage of CBZ, showing serious adverse effects and subsequently treated with a combination of low-dose CBZ and gabapentin (GBP) (group 1); 5 treated with lamotrigine (LMT), showing adverse effects and subsequently treated with GBP (group 2)." | 1.31 | Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. ( Leandri, M; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Kantorová, E | 1 |
| Hnilicová, P | 1 |
| Bogner, W | 1 |
| Grendár, M | 1 |
| Grossmann, J | 1 |
| Kováčová, S | 1 |
| Hečková, E | 1 |
| Strasser, B | 1 |
| Čierny, D | 1 |
| Zeleňák, K | 1 |
| Kurča, E | 1 |
| Swanberg, KM | 1 |
| Prinsen, H | 1 |
| DeStefano, K | 1 |
| Bailey, M | 1 |
| Kurada, AV | 1 |
| Pitt, D | 1 |
| Fulbright, RK | 1 |
| Juchem, C | 1 |
| Bhattacharyya, PK | 1 |
| Phillips, MD | 1 |
| Stone, LA | 1 |
| Lowe, MJ | 1 |
| Cao, G | 2 |
| Edden, RAE | 2 |
| Gao, F | 2 |
| Li, H | 2 |
| Gong, T | 1 |
| Chen, W | 1 |
| Liu, X | 1 |
| Wang, G | 2 |
| Zhao, B | 2 |
| Yin, X | 1 |
| Evans, AC | 1 |
| Xu, J | 1 |
| Li, M | 1 |
| Wang, J | 1 |
| Mori, F | 1 |
| Nisticò, R | 1 |
| Mandolesi, G | 1 |
| Piccinin, S | 1 |
| Mango, D | 1 |
| Kusayanagi, H | 1 |
| Berretta, N | 1 |
| Bergami, A | 1 |
| Gentile, A | 1 |
| Musella, A | 1 |
| Nicoletti, CG | 1 |
| Nicoletti, F | 1 |
| Buttari, F | 1 |
| Mercuri, NB | 1 |
| Martino, G | 1 |
| Furlan, R | 1 |
| Centonze, D | 1 |
| Turcotte, D | 1 |
| Doupe, M | 1 |
| Torabi, M | 1 |
| Gomori, A | 1 |
| Ethans, K | 1 |
| Esfahani, F | 1 |
| Galloway, K | 1 |
| Namaka, M | 1 |
| Yalçınkaya, N | 1 |
| Akcan, U | 1 |
| Örçen, A | 1 |
| Küçükali, Cİ | 1 |
| Türkoğlu, R | 1 |
| Kürtüncü, M | 1 |
| Tüzün, E | 1 |
| Solaro, C | 2 |
| Boehmker, M | 1 |
| Tanganelli, P | 1 |
| Messmer Uccelli, M | 1 |
| Uccelli, A | 1 |
| Leandri, M | 1 |
| Mancardi, GL | 1 |
| Pozdniakov, AV | 1 |
| Tiutin, LA | 1 |
| Bisaga, GN | 1 |
| Odinak, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nabilone Use for Acute Pain in Inflammatory Bowel Disease Patients With Chronic Opioid Use Undergoing Gastrointestinal Surgery: A Single-centered Randomized Controlled Trial[NCT03422861] | 80 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for gamma-aminobutyric acid and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Dronabinol; Female; Gab | 2015 |
Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.
Topics: Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Multiple Sclero | 2009 |
9 other studies available for gamma-aminobutyric acid and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Neurocognitive performance in relapsing-remitting multiple sclerosis patients is associated with metabolic abnormalities of the thalamus but not the hippocampus- GABA-edited 1H MRS study.
Topics: gamma-Aminobutyric Acid; Hippocampus; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multip | 2022 |
In vivo evidence of differential frontal cortex metabolic abnormalities in progressive and relapsing-remitting multiple sclerosis.
Topics: Adult; Aged; Aspartic Acid; Choline; Female; Frontal Lobe; gamma-Aminobutyric Acid; Glutamine; Gluta | 2021 |
Activation volume vs BOLD signal change as measures of fMRI activation - Its impact on GABA - fMRI activation correlation.
Topics: Adult; Case-Control Studies; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Ma | 2017 |
Reduced GABA levels correlate with cognitive impairment in patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Brain; Case-Control Studies; Cognitive Dysfunction; Female; gamma-Aminobutyric Acid; Gyrus Ci | 2018 |
Altered hippocampal GABA and glutamate levels and uncoupling from functional connectivity in multiple sclerosis.
Topics: Adult; Brain Mapping; Cognition; Female; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Humans | 2018 |
Interleukin-1β promotes long-term potentiation in patients with multiple sclerosis.
Topics: Adolescent; Adult; Animals; Encephalomyelitis, Autoimmune, Experimental; Female; gamma-Aminobutyric | 2014 |
Reduced fecal GABA levels in multiple sclerosis patients.
Topics: Body Mass Index; Disability Evaluation; Enzyme-Linked Immunosorbent Assay; Feces; gamma-Aminobutyric | 2016 |
Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Res | 2000 |
[Proton magnetic-resonance spectroscopy in remitting and secondary-progressive multiple sclerosis].
Topics: Adolescent; Adult; Aspartic Acid; Brain; Choline; Creatine; Demyelinating Diseases; Female; gamma-Am | 2001 |